Vanguard files Schedule 13G: ACAD (NASDAQ: ACAD) 8.78M shares, 5.15%
Rhea-AI Filing Summary
Vanguard Portfolio Management reports beneficial ownership of 8,781,007 shares of ACADIA Pharmaceuticals Inc Common Stock. The filing states this equals 5.15% of the class, with 109,362 shares subject to sole voting power and 8,781,007 shares subject to sole dispositive power as of 03/31/2026. The disclosure describes holdings managed across Vanguard Portfolio Management LLC and affiliated business divisions.
Positive
- None.
Negative
- None.
Insights
Large passive stake reported: 8.78M shares, 5.15% of ACAD.
Vanguard Portfolio Management discloses beneficial ownership of 8,781,007 shares, representing 5.15% of ACAD common stock as of 03/31/2026. The filing attributes sole dispositive power to Vanguard entities while voting power is limited to 109,362 shares.
Institutional stake size is near the 5% reporting threshold but does not itself indicate intent to influence governance; subsequent filings would show any changes in voting alignment or director nominations.
Disclosure clarifies control structure across Vanguard affiliates.
The statement explains that dispositive authority is exercised by Vanguard Portfolio Management LLC and affiliated divisions, and that holdings include interests held for funds and managed accounts. The disclosure follows SEC Release No. 34-39538 attribution guidance.
Any governance impact depends on how the voting tranche (109,362 shares) is exercised relative to the larger dispositive position; monitor future proxy or Schedule 13D/A filings for activist or coordinated voting behavior.